Advertisement

Topics

Theravance Company Profile

17:20 EST 10th December 2018 | BioPortfolio

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programmes include: RELVAR™ ELLIPTA™ or BREO™ ELLIPTA™ (FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. 

Location

901 Gateway Blvd.
South San Francisco
California
94080
United States of America

Contact

Phone: 650-808-6000
Email: webmaster@theravance.com


News Articles [51 Associated News Articles listed on BioPortfolio]

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease

DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 c...

Theravance, Mylan's COPD drug gains FDA approval

Theravance Biopharma and Mylan's Yupelri, or revefenacin, was approved by the FDA to treat people with moderate to very sever -More- 

Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

DUBLIN, Aug. 1, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investig...

Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of Yupelri (revefenacin) at the 2018 CHEST Annual Meeting

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan&q...

Theravance secures $250mm via private financing of notes

Theravance Biopharma Inc. secured $250mm (net $230mm) through the private placement of 9% fixed rate term notes due April 15, 2033 from Triple Royalty Sub. The notes are secured by a portion of the fu...

Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of Yupelri in COPD

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ :TBPH ) (“Theravance Biopharma”) and Mylan N.V. (NASDAQ :MYL ) (...

Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of Yupelri (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announc...

Theravance doses first patient in Phase II trial of Crohn’s drug

Theravance Biopharma has dosed the first patient in a Phase II clinical trial assessing the efficacy, safety and tolerability of...Read More... The post Theravance doses first patient in Phase II tria...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discove...

Innoviva, Inc.

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and finan...

More Information about "Theravance" on BioPortfolio

We have published hundreds of Theravance news stories on BioPortfolio along with dozens of Theravance Clinical Trials and PubMed Articles about Theravance for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Theravance Companies in our database. You can also find out about relevant Theravance Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...


Corporate Database Quicklinks



Searches Linking to this Company Record